Capricor Therapeutics shares are trading higher after the company signed a binding term sheet with Nippon Shinyaku for the European expansion and commercialization of Deramiocel for the treatment of Duchenne muscular dystrophy.
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics' shares rose following a binding term sheet with Nippon Shinyaku for the European expansion and commercialization of Deramiocel, a treatment for Duchenne muscular dystrophy.
September 17, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics' stock is up due to a new partnership with Nippon Shinyaku for the European commercialization of Deramiocel, targeting Duchenne muscular dystrophy.
The partnership with Nippon Shinyaku is a significant step for Capricor Therapeutics, as it opens up the European market for Deramiocel. This expansion is likely to increase revenue potential, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100